Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge
Bioconjugate Chemistry · 2023
DOI: 10.1021/acs.bioconjchem.3c00347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Noah Powers und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Mis…. Hauptthemen laut MEDLINE: Vaccines, Opioid-Related Disorders. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NIAID NIH HHS, National Institute on Drug Abuse.
Abstract (Originalsprache)
Currently approved pharmacotherapies for opioid use disorders (OUDs) and overdose reversal agents are insufficient to slow the spread of OUDs due to the proliferation of fentanyl. This is evident in the 31% rise in drug overdose deaths from 2019 to 2022, with rates increasing from 21.6 to 28.3 overdoses per 100,000 deaths. Vaccines are a potential alternative or adjunct therapy for the treatment of several substance use disorders (nicotine, cocaine) but have shown limited clinical success due to suboptimal antibody titers. In this study, we demonstrate that coconjugation of a Toll-like receptor 7/8 (TLR7/8) agonist (UM-3006) alongside a fentanyl-based hapten (F1) on the surface of the carrier protein cross-reactive material 197 (CRM) significantly increased generation of high-affinity fentanyl-specific antibodies. This demonstrated enhanced protection against fentanyl challenges relative to an unconjugated (admix) adjuvant control in mice. Inclusion of aluminum hydroxide (alum) adjuvant further increased titers and enhanced protection, as determined by analysis of fentanyl concentration in serum and brain tissue. Collectively, our findings present a promising approach to enhance the efficacy of antiopioid vaccines, underscoring the need for extensive exploration of TLR7/8 agonist conjugates as a compelling strategy to combat opioid use disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Translational Medicine, Department of Biomedical and Pharmaceutical Sciences, University of Montana, 32 Campus Drive, Skaggs Building, Missoula, Montana 59801, United States.
- Department of Pharmacology, University of Minnesota, Minneapolis, Minnesota 55455, United States.
- Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington 98195, United States.
ORCID-Profile: Noah Powers, Bethany Crouse
Förderung
- NIDA NIH HHS
- NIAID NIH HHS
- National Institute on Drug Abuse
- National Institutes of Health
Zitieren
APA
Powers, N., Massena, C., Crouse, B., Smith, M., Hicks, L., Evans, J. T., Miller, S., Pravetoni, M., & Burkhart, D. (2023). Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00347
Vancouver
Powers N, Massena C, Crouse B, Smith M, Hicks L, Evans JT, et al. Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00347
BibTeX
@article{Powers2023,
author = {Powers, Noah and Massena, Casey and Crouse, Bethany and Smith, Mira and Hicks, Linda and Evans, Jay T and Miller, Shannon and Pravetoni, Marco and Burkhart, David},
title = {Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge},
journal = {Bioconjugate Chemistry},
year = {2023},
doi = {10.1021/acs.bioconjchem.3c00347}
}
EUVIMED